Skip to content

Clinical study of the effect of liposomal bupivacaine for iliac fascia block on perioperative neurocognitive function in elderly patients with hip fracture

Clinical study of the effect of liposomal bupivacaine for iliac fascia block on perioperative neurocognitive function in elderly patients with hip fracture

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400084746
Enrollment
Unknown
Registered
2024-05-23
Start date
2024-05-30
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip fracture

Interventions

Group B:Iliac fascia block using liposomal bupivacaine
Group R:Iliac fascial block using ropivacaine

Sponsors

The First Affiliated Hospital of University of Science and Technology of China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1) Patients with hip fracture, elective total hip arthroplasty, artificial femoral head replacement or intramedullary nail placement 2) Age =65, =90 years old, gender is not limited. 3) BMI: 18-30kg/m2 4) ASA classification II-IV 5) Able to understand and perform NRS score, QoR15 score and delirium scale score, etc. 6) Voluntarily sign the informed consent form and willing to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion criteria: 1) severe cardiac, pulmonary, hepatic and renal dysfunction; 2) History of psychiatric illness or chronic use of psychotropic drugs (dementia, schizophrenia), chronic analgesic drugs, and history of alcoholism; 3) Preoperative Brief Intelligent Mental State Examination Scale (MMSE) <21 points with a diagnosis of moderate-to-severe cognitive impairment; 4) Any cerebrovascular accident such as stroke, transient ischemic attack (TIA) within 3 months; 5) Patients with presence of severe infection; 6) Preoperative PaO2 < 60 mmHg or SpO2 < 92%; 7) Participation in another clinical study of the drug within the last 30 days; 8) Hypersensitivity to the test drug;

Design outcomes

Primary

MeasureTime frame
CAM Scale;MMSE Scale;MoCA Scale;(QoR-15);Pittsburgh Sleep Quality Index;NRS;

Countries

China

Contacts

Public ContactXu Min

The First Affiliated Hospital of University of Science and Technology of China

seumexumin@163.com+86 138 5690 4576

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026